Cargando…

Loss of heterozygosity of TRIM3 in malignant gliomas

BACKGROUND: Malignant gliomas are frequent primary brain tumors associated with poor prognosis and very limited response to conventional chemo- and radio-therapies. Besides sharing common growth features with other types of solid tumors, gliomas are highly invasive into adjacent brain tissue, which...

Descripción completa

Detalles Bibliográficos
Autores principales: Boulay, Jean-Louis, Stiefel, Urs, Taylor, Elisabeth, Dolder, Béatrice, Merlo, Adrian, Hirth, Frank
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2653542/
https://www.ncbi.nlm.nih.gov/pubmed/19250537
http://dx.doi.org/10.1186/1471-2407-9-71
_version_ 1782165291197792256
author Boulay, Jean-Louis
Stiefel, Urs
Taylor, Elisabeth
Dolder, Béatrice
Merlo, Adrian
Hirth, Frank
author_facet Boulay, Jean-Louis
Stiefel, Urs
Taylor, Elisabeth
Dolder, Béatrice
Merlo, Adrian
Hirth, Frank
author_sort Boulay, Jean-Louis
collection PubMed
description BACKGROUND: Malignant gliomas are frequent primary brain tumors associated with poor prognosis and very limited response to conventional chemo- and radio-therapies. Besides sharing common growth features with other types of solid tumors, gliomas are highly invasive into adjacent brain tissue, which renders them particularly aggressive and their surgical resection inefficient. Therefore, insights into glioma formation are of fundamental interest in order to provide novel molecular targets for diagnostic purposes and potential anti-cancer drugs. Human Tripartite motif protein 3 (TRIM3) encodes a structural homolog of Drosophila brain tumor (brat) implicated in progenitor cell proliferation control and cancer stem cell suppression. TRIM3 is located within the loss of allelic heterozygosity (LOH) hotspot of chromosome segment 11p15.5, indicating a potential role in tumor suppression. ... METHODS: Here we analyze 70 primary human gliomas of all types and grades and report somatic deletion mapping as well as single nucleotide polymorphism analysis together with quantitative real-time PCR of chromosome segment 11p15.5. RESULTS: Our analysis identifies LOH in 17 cases (24%) of primary human glioma which defines a common 130 kb-wide interval within the TRIM3 locus as a minimal area of loss. We further detect altered genomic dosage of TRIM3 in two glioma cases with LOH at 11p15.5, indicating homozygous deletions of TRIM3. CONCLUSION: Loss of heterozygosity of chromosome segment 11p15.5 in malignant gliomas suggests TRIM3 as a candidate brain tumor suppressor gene.
format Text
id pubmed-2653542
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-26535422009-03-10 Loss of heterozygosity of TRIM3 in malignant gliomas Boulay, Jean-Louis Stiefel, Urs Taylor, Elisabeth Dolder, Béatrice Merlo, Adrian Hirth, Frank BMC Cancer Research Article BACKGROUND: Malignant gliomas are frequent primary brain tumors associated with poor prognosis and very limited response to conventional chemo- and radio-therapies. Besides sharing common growth features with other types of solid tumors, gliomas are highly invasive into adjacent brain tissue, which renders them particularly aggressive and their surgical resection inefficient. Therefore, insights into glioma formation are of fundamental interest in order to provide novel molecular targets for diagnostic purposes and potential anti-cancer drugs. Human Tripartite motif protein 3 (TRIM3) encodes a structural homolog of Drosophila brain tumor (brat) implicated in progenitor cell proliferation control and cancer stem cell suppression. TRIM3 is located within the loss of allelic heterozygosity (LOH) hotspot of chromosome segment 11p15.5, indicating a potential role in tumor suppression. ... METHODS: Here we analyze 70 primary human gliomas of all types and grades and report somatic deletion mapping as well as single nucleotide polymorphism analysis together with quantitative real-time PCR of chromosome segment 11p15.5. RESULTS: Our analysis identifies LOH in 17 cases (24%) of primary human glioma which defines a common 130 kb-wide interval within the TRIM3 locus as a minimal area of loss. We further detect altered genomic dosage of TRIM3 in two glioma cases with LOH at 11p15.5, indicating homozygous deletions of TRIM3. CONCLUSION: Loss of heterozygosity of chromosome segment 11p15.5 in malignant gliomas suggests TRIM3 as a candidate brain tumor suppressor gene. BioMed Central 2009-02-27 /pmc/articles/PMC2653542/ /pubmed/19250537 http://dx.doi.org/10.1186/1471-2407-9-71 Text en Copyright ©2009 Boulay et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Boulay, Jean-Louis
Stiefel, Urs
Taylor, Elisabeth
Dolder, Béatrice
Merlo, Adrian
Hirth, Frank
Loss of heterozygosity of TRIM3 in malignant gliomas
title Loss of heterozygosity of TRIM3 in malignant gliomas
title_full Loss of heterozygosity of TRIM3 in malignant gliomas
title_fullStr Loss of heterozygosity of TRIM3 in malignant gliomas
title_full_unstemmed Loss of heterozygosity of TRIM3 in malignant gliomas
title_short Loss of heterozygosity of TRIM3 in malignant gliomas
title_sort loss of heterozygosity of trim3 in malignant gliomas
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2653542/
https://www.ncbi.nlm.nih.gov/pubmed/19250537
http://dx.doi.org/10.1186/1471-2407-9-71
work_keys_str_mv AT boulayjeanlouis lossofheterozygosityoftrim3inmalignantgliomas
AT stiefelurs lossofheterozygosityoftrim3inmalignantgliomas
AT taylorelisabeth lossofheterozygosityoftrim3inmalignantgliomas
AT dolderbeatrice lossofheterozygosityoftrim3inmalignantgliomas
AT merloadrian lossofheterozygosityoftrim3inmalignantgliomas
AT hirthfrank lossofheterozygosityoftrim3inmalignantgliomas